EVerMed, Inc.

EVerMed, Inc.

A next-generation biotech venture tackling the root causes of intractable respiratory diseases with EV-based therapies.

Established: April 15, 2024

Location: 3-25-8, Nishi-shinbashi,  Minato-ku, Tokyo

Co-founders: Naoto Matsuda, Representative Director and CEO 

                    Dr. Yu Fujita, Director and CTO 

E-mail: info@evermed.jp

URL: http://evermed.jp/

About EVerMed

EVerMed Inc. is a deep-tech venture founded on April 15, 2024.

Our core technology is based on cutting-edge research into extracellular vesicles (EVs) for the treatment of intractable respiratory diseases. This research is led by Associate Professor Yu Fujita, a leading expert in the EV field, who heads the Department of Next-Generation Drug Discovery at the Center for Medical Sciences, Jikei University School of Medicine.

Dr. Fujita is a respiratory physician and a pioneer in the study of EVs, with a focus on understanding the mechanisms of hard-to-treat respiratory diseases and developing new therapies and regenerative medicine solutions.

Building on Dr. Fujita’s years of research, EM Inc. aims to develop fundamental treatments for respiratory diseases that have traditionally relied only on symptomatic care. We are already advancing a promising drug pipeline, including one candidate with a licensing option agreement signed with a domestic pharmaceutical company—highlighting the strong expectations surrounding our innovations.